miR-143 suppresses epithelial–mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5

Molecular Carcinogenesis

Volumn 55, Issue 12, 2016, Pages 1990-2000

  Zhai, Limin ^a   Ma, Chuanxiang ^b   Li, Wentong ^a   Yang, Shuo ^a   Liu, Zhijun ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b Afflidated Hospital of Weifang Medical University   (China)

Author keywords

breast cancer; EMT; ERK5; GSK 3 ; miR 143

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; MICRORNA 143; MITOGEN ACTIVATED PROTEIN KINASE 7; RNA; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; MICRORNA; MIRN143 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; NORTHERN BLOTTING; OVERALL SURVIVAL; PATIENT; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BREAST; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 7; PROGNOSIS; UP-REGULATION;

EID: 84951816903     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22445     Document Type: Article

References (28)

1. Monroig Pdel C, Chen L, Zhang S, Calin GA. Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Deliv Rev 2015; 81:104–116.
2. Brabletz T. To differentiate or not—Routes towards metastasis. Nat Rev Cancer 2012; 12:425–436.
3. Harquail J, Benzina S, Robichaud GA. MicroRNAs and breast cancer malignancy: An overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 2012; 11:269–280.
4. McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: The potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev 2015; 34:145–155.
5. Xu B, Niu X, Zhang X, et al. MiR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cellular Biochem 2011; 350:207–213.
6. Zhang ZQ, Meng H, Wang N, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol 2014; 9:135.
7. Wang L, Shi ZM, Jiang CF, et al. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget 2014; 5:5416–5427.
8. Clape C, Fritz V, Henriquet C, et al. MiR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 2009; 4:e7542.
9. Nithianandarajah-Jones GN, Wilm B, Goldring CE, Muller J, Cross MJ. ERK5: Structure, regulation and function. Cell Signal 2012; 24:2187–2196.
10. Antoon JW, Martin EC, Lai R, et al. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS ONE 2013; 8:e69291.
11. Miranda M, Rozali E, Khanna KK, Al-Ejeh F. MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments. Oncoscience 2015; 2:99–101.
12. Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 2014; 509:492–496.
13. Truong HH, Xiong J, Ghotra VP, et al. Beta1 integrin inhibition elicits a prometastatic switch through the TGFbeta-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Sci Signal 2014; 7:ra155.
14. Thornton TM, Pedraza-Alva G, Deng B, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008; 320:667–670.
15. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009; 15:416–428.
16. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 2014; 15:1243–1253.
17. Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: Examining the functional consequences of plasticity. Breast cancer Res 2011; 13:226.
18. Lee J, Hahm ER, Marcus AI, Singh SV. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Mol Carcinog 2015, 54:417–429.
19. Volinia S, Nuovo G, Drusco A, et al. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. J Natl Cancer Inst 2014; 106.
20. Li W, Zhai L, Zhao C, Lv S. MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer. Breast Cancer Res Treat 2015; 150:501–509.
21. Zhuang M, Shi Q, Zhang X, et al. Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and B CL2. Tumor Biol 2015; 36:2737–2745.
22. Drew BA, Burow ME, Beckman BS. MEK5/ERK5 pathway: The first fifteen years. Biochim Biophys Acta 2012; 1825:37–48.
23. Castro NE, Lange CA. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast cancer Res 2010; 12:R60.
24. Chen Y, Yu D, Zhang C, et al. Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3beta/beta-catenin pathway. Mol Carcinog 2015; 54:1–8.
25. McCubrey JA, Steelman LS, Bertrand FE, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 2014; 5:2881–2911.
26. Zhu P, Lv J, Yang Z, et al. Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3beta in hepatocellular carcinoma. Biochem Biophys Res Commun 2014; 452:567–574.
27. Lee YK, Lin TH, Chang CF, Lo YL. Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via beta-catenin/GSK-3beta modulation in colorectal carcinoma. PLoS ONE 2013; 8:e82478.
28. Ham YM, Mahoney SJ: Compensation of the AKT signaling by ERK signaling in transgenic mice hearts overexpressing TR IM72. Exp Cell Res 2013; 319:1451–1462.